发布者: 千缘 | 发布时间: 2020-7-28 02:02| 查看数: 120| 评论数: 0|

The US government will pay nearly $2 billion to buyenough of a COVID-19 vaccine being developed byPfizer Inc and German biotech BioNTech SE toinnoculate 50 million people if it proves to be safeand effective, the companies said on Wednesday.


The contract for 100 million doses of the vaccineamounts to a $39 price tag for what is likely to be atwo-dose course of treatment.


The contract is the most the United States has agreed to spend on a vaccine, althoughprevious deals with other vaccine makers were intended to also help pay for developmentcosts.


Pfizer and BioNTech will not receive any money from the government unless their vaccinesucceeds in large clinical trials and can be successfully manufactured, according to a Pfizerspokeswoman.


Under the agreement, the government would also have an option to procure an additional500 million doses. Pfizer said the price for the additional doses would be negotiated separatelyif the US orders them.


The vaccine, if successful, will be made available to Americans at no cost, although theirhealth insurance may be charged, the US department of Health and Human Services (HHS)said.


Pfizer Chief Executive Albert Bourla has said the company intends to make a profit on thevaccine. He has also said that spending its own money, rather than government money todevelop the vaccine should help speed the process.


Pfizer hopes to start its pivotal late-stage trial of the vaccine as early as next week, pendingregulatory approvals, Chief Scientific Officer Mikael Dolsten said in an interview.


"We're already starting to the process of allocating vaccine vials to a variety of differentclinical sites in the US and elsewhere," Dolsten said. "We're looking at the map and gettinggood advice from the CDC. Where do we have the greatest incidence of COVID-19 disease?"


Vaccine trials are more efficient if conducted in areas where high rates of active infection areprevelant.


The vaccine has already shown promise in early-stage small studies in humans, producing thetype of neutralizing antibodies needed to fight the virus. In those trials, subjects received twodoses of the vaccine.


The Pfizer/BioNTech candidate is one of the most advanced of over 150 vaccines beingdeveloped against COVID-19, which has claimed more than 600,000 lives globally and crippledeconomies.


The vaccine utilizes the chemical messenger RNA to instruct cells to make proteins thatmimic the surface of the coronavirus, which the immune system sees as a foreign invader andmounts an attack. Although the technology has been around for years, there has never been anapproved messenger RNA (mRNA)vaccine.


The Trump administration has agreed to spend billions of dollars for the development andprocurement of potential vaccines under its Operation Warp Speed program.


The aim is to produce vaccines that can end the pandemic by protecting billions of peoplefrom infection or severe illness, and governments have signed deals with drugmakers tosecure supplies of various candidates. Whether any will succeed remains far from clear.


Other vaccine makers that have signed deals to receive US government funding for theirefforts include Moderna Inc, AstraZeneca Plc and Novavax Inc.


Pfizer said it will deliver the doses if the product receives emergency use authorization or USapproval as early as October after demonstrating safety and efficacy in a large Phase IIIclinical trial involving up to 30,000 subjects.


Pfizer and BioNTech currently expect to manufacture up to 100 million doses globally by theend of 2020, and potentially more than 1.3 billion doses by the end of 2021, subject to finaldose selection from their clinical trial.


On Monday, the companies agreed to supply the United Kingdom with 30 million doses of thevaccine candidate, but did not disclose a price.


Pfizer shares were up nearly 5%, while BioNTech's US-listed shares were up 13%.



快速回复 返回顶部 返回列表